3/19/2012

A compound by Threshold Pharmaceuticals to treat soft-tissue sarcoma received orphan-drug designation in the EU. The drug, which could get 10 years of market exclusivity, is being tested with standard chemotherapy doxorubicin in a Phase III study.

Full Story:
Reuters

Related Summaries